导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 33.21% | 97/4773 |
| 近一周 | 1.03% | 522/5465 |
| 近一月 | -0.53% | 870/5421 |
| 近一季 | -18.89% | 4831/5231 |
| 近半年 | 26.90% | 97/4920 |
| 近一年 | 57.72% | 49/4394 |
| 近两年 | 279.20% | 27/2954 |
| 近三年 | 269.46% | 4/2253 |
| 成立以来 | 205.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.63% 687/4961 |
64.60% 348/5312 |
- - |
- - |
| 2025 | 115.55% 7/4813 |
-6.50% 3360/3635 |
14.47% 43/4076 |
75.52% 8/4524 |
14.74% 78/4813 |
| 2024 | 31.15% 101/3463 |
11.21% 29/2808 |
2.18% 386/3014 |
11.29% 2533/3129 |
3.71% 776/3463 |
| 2023 | 25.72% 11/2656 |
27.11% 88/2280 |
21.61% 2/2385 |
-13.11% 2132/2515 |
-6.40% 1752/2655 |
| 2022 | -25.21% 1298/2207 |
-17.99% 1285/1919 |
2.45% 1302/2016 |
-12.07% 636/2113 |
1.23% 1334/2208 |
| 2021 | 7.07% 504/1822 |
-6.63% 1024/1255 |
6.19% 762/1330 |
-5.89% 874/1466 |
14.74% 67/1822 |
| 2020 | 1.62% 930/1250 |
4.22% 80/1028 |
8.78% 812/1067 |
-3.65% 1094/1164 |
-6.97% 1149/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.23% 735/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证全指通信设备ETF联接A VS. 长安沪深300非周期A(740101) |